Clinical trial

Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer

NCT02338531

Study summary

ClinicalTrials.gov

Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer

Design: INTERVENTIONAL · Status: WITHDRAWN · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention PF-03084014 Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention Breast cancer surgery Find medicine records · Find other trials using this name

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2015-06-01

PhasePHASE2

Conditions

Breast Cancerverified · MONDO: breast cancer

Interventions

PF-03084014DRUG

Breast cancer surgeryPROCEDURE

Sponsors & collaborators

Jules Bordet Institutelead sponsor

Mapped research locations

ParisFrance1 BrusselsBelgium1 VillejuifFrance1 NamurBelgium1 CharleroiBelgium1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02338531 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.